Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 3, 1996, Pages 357-362

  Thompson, S G ^a   Fechtrup, C ^b   Squire, E ^a   Heyse, U ^b   Breithardt, G ^b   Van de Loo, J C W ^b   Kienast, J ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

angina pectoris; antithrombin III; fibrinogen; hemostatic factors; prognosis

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; PLASMINOGEN; THROMBOCYTE FACTOR 4; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; FEMALE; HEART DEATH; HEART EJECTION FRACTION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029866909     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.3.357     Document Type: Article

References (46)

1. Faster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250, 310-318.
2. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-963.
3. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo J. Hemostatic factors and the risk of developing new coronary events in patients with angina pectoris: principal results of the ECAT Angina Pectoris Study. N Engl J Med. 1995;332:635-641.
4. Meade TW, Chakrabarti RR, Brozovic M, Haines AP, Imeson JD, Mellows S, Miller GJ, North WRS, Stirling Y, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
5. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
6. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
7. Trip MD, Manger Cats V, van Capelle FJL, Vreeken J. Platelet hyperactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;332:1549-1554.
8. Gram J, Jesperson J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. Acta Med Scand. 1987;221:149-153.
9. Hamsten A, DeFaire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
10. Wiman B, Hamsten A. Correlations between fibrinolytic function and acute myocardial infarction. Am J Cardiol. 1990;66:54G-56G.
11. Haines AP, Howarth D, North WRS, Goldenberg E, Stirling Y, Meade TW, Raftery EB, Millar-Craig MW. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost. 1983;50:800-803.
12. Cooper J, Douglas AS. Fibrinogen level as a predictor of mortality in survivors of myocardial infarction. Fibrinolysis. 1991;5:105-108.
13. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J. 1991;66:351-355.
14. Neumann FJ, Katus HA, Hoberg E, Roebruck P, Braun M, Haupt HM, Tillmanns H, Kubler W. Increased plasma viscosity and erythrocyte aggregation: indicators of an unfavourable clinical outcome in patients with unstable angina pectoris. Br Heart J. 1991;66:425-430.
15. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrieili L, Lombardi B, Specchia G, Tavazzi L. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: principal results. Artenoscler Thromb. 1992;12:1063-1070.
16. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991;12:157-161.
17. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 1988;59:101-106.
18. Pelzer H, Schwarz A, Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 1991;65:153-159.
19. Miller GJ, Wilkes HC, Meade TW, Bauer KA, Barzegar S, Rosenberg RD. Haemostatic changes that constitute the hypercoagulable state. Lancet. 1991;338:1079. Letter.
20. Kienast J, Thompson SG, Raskino C, Pelzer H, Fechtrup C, Ostermann H, van de Loo J. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost. 1993;70:550-553.
21. Schmitz-Huebner U, Thompson SG, Balleisen L, Fechtrup C, Grosse-Heitmeyer W, Kirchof B, Most E, Muller U, Seiffert C, Seiffert D, van de Loo J. Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis. Br Heart J. 1988;59:287-291.
22. Judkins MP. Percutaneous transfemoral selective coronary arteriography. Radiol Clin North Am. 1968;6:467-492.
23. Sullivan DR, Marwick THE, Freedman SB. A new method of scoring angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J. 1990;119:1262-1267.
24. Dodge HT, Sandler H, Ballew DW, Lord JD. The use of biplane angiocardiography for the measurement of left ventricular volume in man. Am Heart J. 1960;60:762-776.
25. Kennedy JW, Trenholme SE, Kasser IS. Left ventricular volume and mass from single-plane cineangiocardiogram: a comparison of anteroposterior and right anterior oblique methods. Am Heart J. 1970;80:343-352.
26. Clauss A. Gerinnungsphysiologische Schnellmethode zür Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
27. Laurell CB. Quantitative estimation of protein by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966;15:45-52.
28. Odegard OR. Evaluation of an amidolytic heparin cofactor assay method. Thromb Res. 1975;7:351-360.
29. Altman D. Practical Statistics for Medical Research. London, England: Chapman and Hall; 1991:365-395.
30. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology. 1987;7:1346-1385.
31. Harris EK, Albert A. Survivorship Analysis for Clinical Studies. New York, NY: Marcel Dekker; 1991:127-155.
32. Innerfield I, Goldfisher J, Reichter-Reiss H, Greenberg J. Serum antithrombins in coronary artery disease. Am J Clin Pathol. 1976;65:646-648.
33. Stormorken H, Erikssen J. Plasma antithrombin III and factor VIII antigen in relation to angiographic findings, angina and blood groups in middle-aged men. Thromb Haemost. 1977;38:874-878.
34. Baker IA, Eastham R, Elwood PC, Etherington M, O'Brien JR, Sweetnam PM. Haemostatic factors associated with ischaemic heart disease in men aged 45 to 64 years: the Speedwell study. Br Heart J. 1982;47:490-494.
35. Gonzales R, Vicente V, Alegre A, Pabon P, Alberca I. Protein C and antithrombin III in acute myocardial infarction. Thromb Res. 1986;43:681-685.
36. Yue RH, Gertler MM, Starr T, Koutrouby R. Alteration of plasma antithrombin III levels in ischaemic heart disease. Thromb Haemost. 1976;35:598-606.
37. Meade TW. Epidemiology of atheroma, thrombosis and ischaemic heart disease. In: Bloom AL, Thomas DP, eds. Haemostasis and Thrombosis. 2nd ed. Edinburgh, Scotland: Churchill Livingstone; 1987:697-720.
38. Folsom AR, Wu KK, Shahar E, Davis CE, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb. 1993;13:1829-1836.
39. ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J. 1993;14:8-17.
40. Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. Lancet. 1991;338:850-851.
41. Cortellaro M for the PLAT Study Group. Antithrombin III and arterial disease. Lancet. 1991;338:1525-1526.
42. Frebelius S, Hedin U, Swedenborg J. Thrombogenicity of the injured vessel wall: role of antithrombin and heparin. Thromb Haemost. 1994;71:147-153.
43. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease - the Framingham study: a 34-year follow-up. Am Heart J. 1994;127:674-682.
44. Conlan MG, Folsom AR, Finch A, Davis CE, Marcucci G, Sortie P, Wu KK. Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. Thromb Haemost. 1994;72:551-556.
45. Levine SP, Lindenfeld J, Brant Ellis J, Raymond NM, Krentz LS. Increased plasma concentrations of platelet factor 4 in coronary artery disease. Circulation. 1981;64:626-632.
46. Nichols AB, Owen J, Kaplan KL, Sciacca RR, Cannon PJ, Nossel HL. Fibrinopeptide A, platelet factor 4, and β-thromboglobulin levels in coronary heart disease. Blood. 1982;60:650-654.